Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Tsang
Observed name:
David J. Tsang
Observed institutions:
The Royal Melbourne Hospital,
Royal Marsden NHS Foundation Trust,
Institute of Cancer Research,
St James's University Hospital,
Southend Hospital,
Western Health,
Royal Marsden Hospital,
Velindre Cancer Centre,
Cardiff University,
University of Birmingham
show all 10
OpenAlex ID:
A5111487765
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
2015
·
Nicholas D James
, Matthew R Sydes
, et al.
·
The Lancet
·
1,979
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
2020
·
John A Bridgewater
, Siân A Pugh
, et al.
·
The Lancet Oncology
·
252
PDF
SMARTphone-based, early cardiac REHABilitation in patients with acute coronary syndromes: a randomized controlled trial
2020
·
Matias B. Yudi
, David J. Clark
, et al.
·
Coronary Artery Disease
·
76
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
2017
·
Malcolm D. Mason
, Noel W. Clarke
, et al.
·
Journal of Clinical Oncology
·
73
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
2024
·
Chris C Parker
, Noel W Clarke
, et al.
·
The Lancet
·
53
SMARTphone-based, early cardiac REHABilitation in patients with acute coronary syndromes [SMART-REHAB Trial]: a randomized controlled trial protocol
2016
·
Matias B. Yudi
, David J. Clark
, et al.
·
BMC Cardiovascular Disorders
·
35
PDF
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
2018
·
Beth S. Woods
, Eleftherios Sideris
, et al.
·
European Urology Oncology
·
27
PDF
Aggressive combined-modality therapy for squamous cell carcinoma of the female urethra
2008
·
Steve Nicholson
, David Tsang
, et al.
·
Nature Clinical Practice Urology
·
8
Audit of safety and quality of the use of enoxaparin for anticoagulation in continuous renal replacement therapy
2011
·
David J. Tsang
, Annabel Tuckfield
, et al.
·
Critical Care and Resuscitation
·
6
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
2025
·
Gianmarco Leone
, Francesco Orlando
, et al.
·
JAMA Oncology
·
5
Coronary Angiographic Findings in Patients With and Without St-segment Elevation on Ecg After Successful Resuscitation From Out-of-hospital Cardiac Arrest
2015
·
David Tsang
, Matias Yudi
, et al.
·
Journal of the American College of Cardiology
PDF
PM197 Clinical Characteristics, Trends and Outcomes in Elderly Patients with Acute Coronary Syndromes Undergoing PCI
2014
·
Matias Yudi
, Nick Andrianopoulos
, et al.
·
Global Heart
PM147 Newer generation drug eluting stent (DES) use in STEMI PCI
2014
·
Matthew J. Brooks
, Jeffrey Lefkovits
, et al.
·
Global Heart
Show more works
View as search
Works count:
13
Citation count:
2,510
H-index:
8
I10-index:
7
Year
Topic
Type